首页> 美国卫生研究院文献>Medicina >Ventilator-Associated Pneumonia due to Drug-Resistant Acinetobacter baumannii: Risk Factors and Mortality Relation with Resistance Profiles and Independent Predictors of In-Hospital Mortality
【2h】

Ventilator-Associated Pneumonia due to Drug-Resistant Acinetobacter baumannii: Risk Factors and Mortality Relation with Resistance Profiles and Independent Predictors of In-Hospital Mortality

机译:耐药鲍曼不动杆菌引起的呼吸机相关性肺炎:危险因素和死亡率与耐药性的关系以及院内死亡率的独立预测因子

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background and objectives: High mortality and healthcare costs area associated with ventilator-associated pneumonia (VAP) due to Acinetobacter baumannii (A. baumannii). The data concerning the link between multidrug-resistance of A. baumannii strains and outcomes remains controversial. Therefore, we aimed to identify the relation of risk factors for ventilator-associated pneumonia (VAP) and mortality with the drug resistance profiles of Acinetobacter baumannii (A. baumannii) and independent predictors of in-hospital mortality. Methods: A retrospective ongoing cohort study of 60 patients that were treated for VAP due to drug-resistant A. baumannii in medical-surgical intensive care units (ICU) over a two-year period was conducted. Results: The proportions of multidrug-resistant (MDR), extensively drug-resistant (XDR), and potentially pandrug-resistant (pPDR) A. baumannii were 13.3%, 68.3%, and 18.3%, respectively. The SAPS II scores on ICU admission were 42.6, 48.7, and 49 (p = 0.048); hospital length of stay (LOS) prior to ICU was 0, one, and two days (p = 0.036), prior to mechanical ventilation (MV)—0, 0, and three days (p = 0.013), and carbapenem use prior to VAP—50%, 29.3%, and 18.2% (p = 0.036), respectively. The overall in-hospital mortality rate was 63.3%. In MDR, XDR, and pPDR A. baumannii VAP groups, it was 62.5%, 61.3%, and 72.7% (p = 0.772), respectively. Binary logistic regression analysis showed that female gender (95% OR 5.26; CI: 1.21–22.83), SOFA score on ICU admission (95% OR 1.28; CI: 1.06–1.53), and RBC transfusion (95% OR 5.98; CI: 1.41–25.27) were all independent predictors of in-hospital mortality. Conclusions: The VAP risk factors: higher SAPS II score, increased hospital LOS prior to ICU, and MV were related to the higher resistance profile of A. baumannii. Carbapenem use was found to be associated with the risk of MDR A. baumannii VAP. Mortality due to drug-resistant A. baumannii VAP was high, but it was not associated with the A. baumannii resistance profile. Female gender, SOFA score, and RBC transfusion were found to be independent predictors of in-hospital mortality.
机译:背景与目的:鲍曼不动杆菌(鲍曼不动杆菌)引起的呼吸机相关性肺炎(VAP)相关的高死亡率和医疗费用。关于鲍曼不动杆菌菌株的多药耐药性与预后之间的联系的数据仍存在争议。因此,我们旨在确定呼吸机相关性肺炎(VAP)和死亡率的危险因素与鲍曼不动杆菌(A. baumannii)的耐药性以及医院内死亡率的独立预测因子之间的关系。方法:一项为期两年的回顾性正在进行的队列研究,对60名因耐药性鲍曼不动杆菌而在医疗外科重症监护病房(ICU)中接受过VAP治疗的患者进行了研究。结果:鲍曼不动杆菌的多重耐药性(MDR),广泛耐药性(XDR)和潜在的耐泛药性(pPDR)的比例分别为13.3%,68.3%和18.3%。重症监护病房入院的SAPS II评分分别为42.6、48.7和49(p = 0.048);重症监护病房之前的住院天数(LOS)为0、1和2天(p = 0.036),机械通气(MV)之前为0、0和3天(p = 0.013),而碳青霉烯在使用之前VAP-分别为50%,29.3%和18.2%(p = 0.036)。整体院内死亡率为63.3%。在MDR,XDR和pPDR鲍曼不动杆菌VAP组中,分别为62.5%,61.3%和72.7%(p = 0.772)。二元逻辑回归分析显示,女性(95%或5.26; CI:1.21–22.83),入住ICU的SOFA评分(95%或1.28; CI:1.06-1.53​​)和RBC输血(95%OR 5.98; CI: 1.41–25.27)都是院内死亡率的独立预测因子。 结论: VAP危险因素:较高的SAPS II评分,ICU之前的住院LOS增加和MV与 A的较高耐药性有关。鲍曼氏菌。发现碳青霉烯的使用与MDR A的风险有关。 Baumannii VAP。因抗药性 A而导致的死亡率。鲍曼氏菌VAP较高,但与 A无关。鲍曼氏菌的耐药性发现女性,SOFA评分和RBC输血是院内死亡率的独立预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号